Navigation Links
DermTech and Rady Children's Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
Date:10/27/2008

DermTech's Non-invasive EGIR Technology to be Employed to Generate Genetic,

Objective Data on Therapy Response

LA JOLLA, Calif., Oct 27 /PRNewswire/ -- DermTech, a biotechnology company developing EGIR(TM) (Epidermal Genetic Information Retrieval) technology for the non-invasive early detection of melanoma, drug development and other applications, and Rady Children's Hospital-San Diego, today announced the initiation of a study involving the use of the company's EGIR technology as a vehicle to evaluate oral and/or topical Vitamin D as a treatment for atopic dermatitis (eczema).

"We are looking forward to working with the team at DermTech and employing the company's non-invasive EGIR ("tape stripping") technology as part of our research," said Lawrence F. Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology, Rady Children's Hospital and the Principal Investigator on the study. "Atopic dermatitis is a condition that gets little public attention but can have a major negative impact on a child or young adult's quality of life. A recent small study has suggested that Vitamin D may help bolster the skin's immune responses, but more data is needed. We will be using the EGIR technology to evaluate the expression of defense proteins in the affected population before and after treatment with Vitamin D to help elucidate a potentially important part of atopic dermatitis immunology and therapy."

Atopic dermatitis is a common, chronic inflammatory skin disease with complex immunologic features. It has 15-20% prevalence in children within the first decade of life and there are limited therapeutic options.

In "normal skin", anti-microbial peptides (AMP) such as cathelicidin (hCAP18/LL37) help regulate innate immunity by directly killing microbes including Gram-positive and Gram-negative bacteria, as well as fungi and certain viruses. Patients with atopic dermatitis however, lack sufficient expression of these AMPs and
'/>"/>

SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
4. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. ABR-Affinity BioReagents to Participate in the American Association for Cancer Research Meeting in San Diego, California, April 12 - 16, 2008
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) ... press release disseminated this morning by PR Web, and ... press release states that Immunovaccine has entered into a ... release did not originate from Immunovaccine and there is ... release. Please note that all official statements by ...
(Date:2/27/2015)... and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the ... report to their offering. , Global Market ... on Trypsin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)...   PureTech , a science and technology R&D ... and technologies in the healthcare sector, announced today the ... Member of the Board of Directors of Sanofi, to ... been a pleasure to know Chris for many years ... working together more closely now," said Dr. Robert ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... 2011 Ardea Biosciences, Inc. (Nasdaq: RDEA ... underwritten public offering of 2,750,000 shares of its common ... $26.00 per share. The gross proceeds to Ardea from ... deducting the underwriting discount and other estimated offering expenses ...
... 2011 CSL Behring , a global leader ... of CSL Limited (ASX:CSL), has awarded advocacy ... the Local Empowerment for Advocacy Development (LEAD) program. LEAD ... to helping people who use plasma-derived or recombinant therapies ...
... 20, 2011 Bacterin International Holdings, Inc. ("Bacterin") ... it has closed on the Bridge Bank, N.A. revolving accounts ... that was announced on November 22, 2010.  The financing, which ... has a 2 year term and carries an interest rate ...
Cached Biology Technology:Ardea Biosciences Prices Public Offering of Common Stock 2Ardea Biosciences Prices Public Offering of Common Stock 3CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington 2CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington 3CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington 4Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank 2Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank 3
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... emerged as a promising alternative for the ... tissues, circumventing the complications associated with traditional ... regenerate damaged tissue by using engineered tissue ... and eventually integrate into the host tissue. ...
... type 1 diabetes, lupus and rheumatoid arthritis occur when ... have not known precisely where the molecular breakdowns responsible ... from the Whitehead Institute and the Dana-Farber Cancer Institute ... at the core of autoimmune disease, findings that may ...
... been considered an exclusively human activity, but now at least ... for tomorrow. The finding also raises the intriguing possibility that, ... published today (22 February) in the journal Nature shows that ... by caching food. The birds are shown to have learned ...
Cached Biology News:Cracking open the black box of autoimmune disease 2Birds found to plan for the future 2
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... 295 ex can measure three fluorescence lifetimespicoseconds ... a few minutes. To match the absorption ... tryptophan, the Protein 295 exs excitation source ... emitting 295 nm. Fluorescence of tryptophan is ...
... Microarrays designed for proteomic scale kinase ... and drug discovery research built on the ... platform. These microarrays are available as part ... Peptide Microarray Service. Probe Content ...
... The F-7000 is a research grade ... bandwidth and scanning speeds of up to ... provides a high concentrated light beam along ... works with our FL Solutions, PC fluorescence ...
Biology Products: